Advantech launches DICOM Part 14 compliant LCD kits for medical imaging applications
Advantech, a global embedded solutions provider, will feature its first DICOM Part 14 compliant 21.5” FHD LCD kit next month at Medica in Düsseldorf, Germany (Stand 9A74; 18-21 November, 2019).
The IDK-1121MD series is geared specifically toward medical imaging applications. With a 21.5” Full HD IPS display and a scaler board supporting DICOM part 14 gamma calibrations, the IDK-1121MD series offers wide viewing angles, as well as accurate, high-quality image reproduction. The series is equipped with an independent 6-axis colour adjustment function so customers can adjust for precise and accurate colour performance. IDK-1121MD gives customers maximum mechanical design flexibility to fit their own systems such as ultrasound and surgical imaging.
High resolution IPS display represents perfect images
Unlike other industrial applications, medical imaging displays require consistent and accurate imaging across different display devices. The IDK-1121MD series is designed with 21.5” wide-display and LED backlit. Full HD resolution makes the images on display appear sharper and clearer with 2 megapixel high-resolution. Equipped with IPS technology, IDK-1121MD displays consistent and accurate colour from all viewing angles.
DICOM Part 14 Compliance ensures consistent image quality
The IDK-1121MD integrates with an in-house designed scaler board to support precise calibration compliant with the DICOM Part 14 standard and VGA/DVI/DP interfaces. Utilising 10-bit simultaneous grayscale, IDK-1121MD can display over one billion colours to provide a highly accurate greyscale representation. In addition, its 6-axis colour adjustment function helps customers adjust colour to best meet their application needs. Auto brightness sensors and RS-232 for the remote control function are also available via customisation.
The IDK-1121MD is available for order now. For more information, please contact an Advantech local sales office or visit www.advantech.com
Comment on this article below or via Twitter: